These observations, together with the predictive power of CD8+PD-1+ T cells, form an independent layer of evidence, on top of the clinical data, that atezolizumab has an additive effect together with chemotherapy in eliciting responses in G/GEJ cancers. This evidence concerns the gene PDCD1 and cancer.